Skip to content
Home/Companies/Healthcare / Biotech/Calliditas
Calliditas

Calliditas

Healthcare / Biotech·Sweden·Exited 2024·Held 4yr
Entry
2020
Hold
4yr
Exit
2024

Who owns Calliditas?

Calliditas was owned by Sofinnova Partners through Sofinnova Crossover Fund I (2018 vintage) from 2020 to 2024, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-04-21

Sofinnova Partners
Investor
Sofinnova Partners
Sofinnova Crossover Fund I · 2018 · VC

Key facts

HQSweden
SectorHealthcare / Biotech
Websitewww.calliditas.se
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2024

More from Sofinnova Crossover Fund I

Other portfolio companies in the same fund.

GenSight Biologics
GenSight Biologics
Active
BiotechFrance
Amolyt Pharma
Amolyt Pharma
Exited 2024
BiotechFrance· 2021
to
Sphere Bio (formerly Sphere Fluidics)
Sphere Bio (formerly Sphere Fluidics)
Exited 2025
MedTechUK· 2021
to
Artios Pharma
Artios Pharma
Active
BiotechUK· 2020
Hemab Therapeutics
Hemab Therapeutics
Active
BiotechDenmark· 2020
F2G
F2G
Active
BiotechUK· 2019

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Calliditas

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Calliditas?

1 strategic and 119financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Calliditas.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue